A Multiomics Study Based on the Dynamic Evolution of Endometrial Carcinogenesis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorRenJi Hospital
About this trial
The goal of this observational study is to draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of the dynamic evolution of endometrial carcinogenesis in 100 patients with normal endometrium, 100 patients with atypical endometrial hyperplasia, and 100 patients with endometrial cancer; and then to explore the underlying molecular mechanism, and establish the database system for the dynamic evolution of endometrial carcinogenesis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Pathological diagnosis: normal endometrium, atypical hyperplasia endometrium, or endometrial cancer;
Obtain pathological results after undergoing hysteroscopic surgery or hysterectomy;
The patient voluntarily participated in this research project with good compliance and was able to complete the enrollment according to the experimental requirements;
Sign the informed consent form and consent to the collection and use of their data, and consent to genomics, transcriptome and other tests.
Disqualifiers
Patients with malignant tumors in other parts of the body;
Suffering from uncontrollable neurological diseases, psychiatric diseases, or psychiatric disorders;
Poor compliance and inability to cooperate and describe treatment responders.
Trial population
Patients with normal endometrium (requiring diagnostic or therapeutic hysteroscopy or hysterectomy for other reasons), patients with precancerous lesions of endometrium, and patients with endometrial cancer who underwent surgery in the gynecology and obstetrics department of Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, whose illness was diagnosed as normal endometrium, atypical hyperplasia endometrium, or endometrial cancer by pathology.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
300 Participants
are grouped into 3 trial groupsGroup A: Normal Group
Group B: Precancerous Group
Group C: Carcinoma Group
Trial outcomes
Primary outcomes
1
The mutant genes of participants and their expression as assessed by gene sequencing, RNA sequencing and mass spectrometry analysis
Time frame
August 2023 to June 20262
Differences in the expression of these mutant genes among the three groups of participants as assessed by SAS® 9.4
Time frame
January 2026 to June 2026Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: